Pulmonary Fibrosis Stakeholder Summit: A Joint NHLBI, Three Lakes Foundation, and Pulmonary Fibrosis Foundation Workshop Report.

Autor: Montesi SB; Division of Pulmonary and Critical Care Medicine and., Gomez CR; Division of Lung Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland., Beers M; Pulmonary and Critical Care Division, University of Pennsylvania, Philadelphia, Pennsylvania., Brown R; Program in Neurotherapeutics, University of Massachusetts Chan Medical School, Worchester, Massachusetts., Chattopadhyay I; Deparment of Medicine, University of Chicago, Chicago, Illinois., Flaherty KR; Division of Pulmonary and Critical Care Medicine., Garcia CK; Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Irving Medical Center, New York, New York., Gomperts B; Department of Pediatrics, David Geffen School of Medicine., Hariri LP; Division of Pulmonary and Critical Care Medicine and.; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts., Hogaboam CM; Women's Guild Lung Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California., Jenkins RG; National Heart and Lung Institute, Imperial College London, London, United Kingdom., Kaminski N; Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Yale School of Medicine, New Haven, Connecticut., Kim GHJ; Center for Computer Vision and Imaging Biomarkers, Department of Radiological Sciences, David Geffen School of Medicine, and.; Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, California., Königshoff M; Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania., Kolb M; Division of Respirology, McMaster University, Hamilton, Ontario, Canada., Kotton DN; Center for Regenerative Medicine, Boston University and Boston Medical Center, Boston, Massachusetts., Kropski JA; Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Lasky J; Pulmonary Fibrosis Foundation, Chicago, Illinois.; Department of Medicine, Tulane University, New Orleans, Louisiana., Magin CM; Department of Bioengineering.; Department of Pediatrics.; Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, and., Maher TM; Keck School of Medicine, University of Southern California, Los Angeles, California., McCormick M; Pulmonary Fibrosis Foundation, Chicago, Illinois., Moore BB; Department of Microbiology and Immunology, and., Nickerson-Nutter C; Three Lakes Foundation, Northbrook, Illinois., Oldham J; Division of Pulmonary and Critical Care Medicine., Podolanczuk AJ; Division of Pulmonary and Critical Care, Weill Cornell Medical College, New York, New York., Raghu G; Division of Pulmonary, Sleep and Critical Care Medicine, University of Washington, Seattle, Washington., Rosas I; Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, Texas; and., Rowe SM; Department of Medicine and.; Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, Alabama., Schmidt WT; Pulmonary Fibrosis Foundation, Chicago, Illinois., Schwartz D; Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado., Shore JE; Pulmonary Fibrosis Foundation, Chicago, Illinois., Spino C; Department of Biostatistics, University of Michigan, Ann Arbor, Michigan., Craig JM; Division of Lung Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland., Martinez FJ; Division of Pulmonary and Critical Care, Weill Cornell Medical College, New York, New York.
Jazyk: angličtina
Zdroj: American journal of respiratory and critical care medicine [Am J Respir Crit Care Med] 2024 Feb 15; Vol. 209 (4), pp. 362-373.
DOI: 10.1164/rccm.202307-1154WS
Abstrakt: Despite progress in elucidation of disease mechanisms, identification of risk factors, biomarker discovery, and the approval of two medications to slow lung function decline in idiopathic pulmonary fibrosis and one medication to slow lung function decline in progressive pulmonary fibrosis, pulmonary fibrosis remains a disease with a high morbidity and mortality. In recognition of the need to catalyze ongoing advances and collaboration in the field of pulmonary fibrosis, the NHLBI, the Three Lakes Foundation, and the Pulmonary Fibrosis Foundation hosted the Pulmonary Fibrosis Stakeholder Summit on November 8-9, 2022. This workshop was held virtually and was organized into three topic areas: 1 ) novel models and research tools to better study pulmonary fibrosis and uncover new therapies, 2 ) early disease risk factors and methods to improve diagnosis, and 3 ) innovative approaches toward clinical trial design for pulmonary fibrosis. In this workshop report, we summarize the content of the presentations and discussions, enumerating research opportunities for advancing our understanding of the pathogenesis, treatment, and outcomes of pulmonary fibrosis.
Databáze: MEDLINE